ABIE:XETRA:XETRA-AXA IM ACT Biodiversity Equity UCITS ETF EUR(H) Acc (EUR)

ETF | Others |

Last Closing

USD 13.148

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-09 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.77 (-1.46%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 191.96B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.40 (-1.38%)

USD 177.46B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.38 (-1.37%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.39 (-1.54%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.78 (-1.67%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

-2.26 (-1.55%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.73 (-1.40%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.36 (-0.34%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+0.36 (+0.06%)

USD 80.38B

ETFs Containing ABIE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.76% 59% D- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.76% 59% D- 62% D
Trailing 12 Months  
Capital Gain 25.34% 70% C- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.34% 70% C- 71% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.60% 53% F 53% F
Dividend Return 6.60% 52% F 51% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.34% 68% D+ 75% C
Risk Adjusted Return 79.17% 76% C+ 79% B-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike